RU2438660C2 - Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей - Google Patents

Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей Download PDF

Info

Publication number
RU2438660C2
RU2438660C2 RU2006132036/15A RU2006132036A RU2438660C2 RU 2438660 C2 RU2438660 C2 RU 2438660C2 RU 2006132036/15 A RU2006132036/15 A RU 2006132036/15A RU 2006132036 A RU2006132036 A RU 2006132036A RU 2438660 C2 RU2438660 C2 RU 2438660C2
Authority
RU
Russia
Prior art keywords
glycopyrrolate
inhalation
formoterol
drug according
salmeterol
Prior art date
Application number
RU2006132036/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2006132036A (ru
Inventor
Иоахим ГЕДЕ (DE)
Иоахим Геде
Петер Йорген КНОТА (DE)
Петер Йорген КНОТА
Иоахим МАУС (DE)
Иоахим Маус
Иштван СЕЛЕНЬИ (DE)
Иштван СЕЛЕНЬИ
Original Assignee
Меда Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Меда Фарма Гмбх Унд Ко. Кг filed Critical Меда Фарма Гмбх Унд Ко. Кг
Publication of RU2006132036A publication Critical patent/RU2006132036A/ru
Application granted granted Critical
Publication of RU2438660C2 publication Critical patent/RU2438660C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RU2006132036/15A 2004-02-06 2005-01-24 Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей RU2438660C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195704P 2004-02-06 2004-02-06
US60/541,957 2004-02-06

Publications (2)

Publication Number Publication Date
RU2006132036A RU2006132036A (ru) 2008-03-20
RU2438660C2 true RU2438660C2 (ru) 2012-01-10

Family

ID=34837534

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006132036/15A RU2438660C2 (ru) 2004-02-06 2005-01-24 Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей

Country Status (19)

Country Link
US (3) US20050175549A1 (https=)
EP (1) EP1718336B1 (https=)
JP (1) JP5524442B2 (https=)
CN (1) CN1905902A (https=)
AT (1) ATE399027T1 (https=)
AU (1) AU2005210083B2 (https=)
CA (1) CA2550841C (https=)
CY (1) CY1108326T1 (https=)
DE (1) DE602005007708D1 (https=)
DK (1) DK1718336T3 (https=)
ES (1) ES2309705T3 (https=)
HR (1) HRP20080439T3 (https=)
NO (1) NO337128B1 (https=)
NZ (1) NZ548302A (https=)
PL (1) PL1718336T3 (https=)
PT (1) PT1718336E (https=)
RU (1) RU2438660C2 (https=)
SI (1) SI1718336T1 (https=)
WO (1) WO2005074900A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1713473B1 (en) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US20080031828A1 (en) * 2006-08-03 2008-02-07 Boehringer Ingelheim International Gmbh Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
ES2467928T3 (es) * 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
EP2515853B1 (en) * 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
UA113832C2 (xx) * 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
EP2749283A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and olodaterol
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2835927A1 (en) * 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
LT3096737T (lt) * 2013-12-30 2018-06-11 Chiesi Farmaceutici S.P.A. Stabili glikopironio bromido ir formoterolio derinio suspausto aerozolio tirpalo kompozicija
EP3384898A1 (en) 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2017077488A1 (en) * 2015-11-04 2017-05-11 Glenmark Pharmaceuticals Limited An inhalable fixed dose powder composition comprising glycopyrronium and formoterol
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204285B1 (en) * 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
CA2405705A1 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
WO2001076601A2 (en) * 2000-04-07 2001-10-18 Glaxo Group Limited Pharmaceutical compositions comprising salmeterol and ipratropium
US6645466B1 (en) * 1998-11-13 2003-11-11 Jago Research Ag Dry powder for inhalation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0937041T3 (da) 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204285B1 (en) * 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
US6645466B1 (en) * 1998-11-13 2003-11-11 Jago Research Ag Dry powder for inhalation
CA2405705A1 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
WO2001076601A2 (en) * 2000-04-07 2001-10-18 Glaxo Group Limited Pharmaceutical compositions comprising salmeterol and ipratropium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DWPI, реферат. *

Also Published As

Publication number Publication date
DK1718336T3 (da) 2008-10-20
EP1718336B1 (en) 2008-06-25
CY1108326T1 (el) 2014-02-12
CA2550841A1 (en) 2005-08-18
WO2005074900A2 (en) 2005-08-18
SI1718336T1 (sl) 2008-10-31
ES2309705T3 (es) 2008-12-16
US20070270481A1 (en) 2007-11-22
JP5524442B2 (ja) 2014-06-18
US20050175549A1 (en) 2005-08-11
HRP20080439T3 (hr) 2008-10-31
PL1718336T3 (pl) 2008-11-28
ATE399027T1 (de) 2008-07-15
NO20063882L (no) 2006-10-26
US20060252815A1 (en) 2006-11-09
NO337128B1 (no) 2016-01-25
RU2006132036A (ru) 2008-03-20
AU2005210083A1 (en) 2005-08-18
DE602005007708D1 (de) 2008-08-07
NZ548302A (en) 2010-04-30
AU2005210083B2 (en) 2010-03-11
EP1718336A2 (en) 2006-11-08
WO2005074900A3 (en) 2006-04-06
PT1718336E (pt) 2008-08-28
JP2007520506A (ja) 2007-07-26
CA2550841C (en) 2012-10-02
CN1905902A (zh) 2007-01-31
US7985766B2 (en) 2011-07-26

Similar Documents

Publication Publication Date Title
RU2438660C2 (ru) Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
CA2368583C (en) New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics
RU2238085C2 (ru) Композиции, включающие формотерол и соль тиотропия
DK2968312T3 (en) drug combination
RU2019100425A (ru) Новая доза и препаративная форма
CA2828640C (en) Use of glycopyrrolate for treating tachycardia
EA023839B1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
WO2009090010A1 (en) Compositions comprising an antimuscarinic and a long-acting beta-agonist
CA2688542C (en) Methods and compositions for administration of oxybutynin
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
JP2014518894A (ja) ウメクリジニウムを含む乾燥粉末インヘラー組成物
CA2519682A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
AU2003292120A1 (en) New synergistic combination comprising roflumilast and formoterol
US20060199865A1 (en) Synergistic combination comprising roflumilast and (r,r) - formoterol
MXPA06008936A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND beta MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
HK1098355A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2004084894A1 (en) Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
NZ614603B2 (en) Use of glycopyrrolate for treating tachycardia

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090629

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20100625